Drug
Vidofludimus-calcium clinical trials
Also written vidofludimus calcium and IMU-838.
A product of Vidofludimus; its studies count on that page too.
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 1
Immunic AG (6) · University Hospitals Coventry and Warwickshire NHS Trust (1)
Studies
Open first, then newest update. How each study uses vidofludimus-calcium is read from its arms, and is right about nine times in ten.
Testing it · 7
- Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisActive, not recruitingPhase 3Immunic AGNCT05134441Written as IMU-838 tablets
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisActive, not recruitingPhase 3Immunic AGNCT05201638Written as IMU-838 tablets
- A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)CompletedPhase 2/3Immunic AGNCT04379271Written as IMU-838
- Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisActive, not recruitingPhase 2Immunic AGNCT05054140Written as IMU-838
- MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)Active, not recruitingPhase 2Immunic AGNCT03846219Written as IMU-838 (30 mg/day)
- Phase 2 Dose-finding IMU-838 for Ulcerative ColitisTerminatedPhase 2Immunic AGNCT03341962Written as IMU-838
- IMU-838 and Oseltamivir in the Treatment of COVID-19CompletedPhase 2University Hospitals Coventry and Warwickshire NHS TrustNCT04516915Written as IMU-838
Codes
What other systems call vidofludimus-calcium · ClinicalTrials.gg INT016601
- UNII (FDA) FW5VY7926XVIDOFLUDIMUS CALCIUM ANHYDROUSConfirmed FDA, Wikidata
- Wikidata Q130466805vidofludimus-calciumConfirmed FDA, Wikidata
- NCI Thesaurus C172652Vidofludimus Calcium AnhydrousOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FW5VY7926X | VIDOFLUDIMUS CALCIUM ANHYDROUS | Confirmed FDA, Wikidata |
| Wikidata | Q130466805 | vidofludimus-calcium | Confirmed FDA, Wikidata |
| NCI Thesaurus | C172652 | Vidofludimus Calcium Anhydrous | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.